Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorCatli, Gonul
dc.contributor.authorAbaci, Ayhan
dc.contributor.authorBober, Ece
dc.contributor.authorBuyukgebiz, Atilla
dc.date.accessioned2019-08-13T12:10:23Z
dc.date.accessioned2019-08-13T16:03:15Z
dc.date.available2019-08-13T12:10:23Z
dc.date.available2019-08-13T16:03:15Z
dc.date.issued2013
dc.identifier.issn0334-018X
dc.identifier.issn2191-0251
dc.identifier.urihttps://dx.doi.org/10.1515/jpem-2012-0327
dc.identifier.urihttp://hdl.handle.net/11446/3039
dc.descriptionWOS: 000316895000001en_US
dc.descriptionPubMed ID: 23327784en_US
dc.description.abstractPituitary adenoma is the most common cause of hyperprolactinemia, which is a rare endocrine disorder encountered in pediatric patient care. Epidemiological and clinical information about hyperprolactinemia in childhood and adolescence is limited. Clinical signs of hyperprolactinemia are very heterogeneous. In girls, disturbances in menstrual function and galactorrhea may be seen, whereas in boys, headache, visual disturbances, delayed pubertal development and hypogonadism are often present. Owing to the ease of ordering a serum prolactin measurement, an evidence-based, cost-effective approach to the management of this endocrine disorder is required. Before a diagnosis of hyperprolactinemia is made, drug use, renal insufficiency, hypothyroidism, and parasellar tumors should be excluded. The main objectives of treatment are normalization of prolactin level, adenoma shrinkage, and recovery from clinical signs related to hyperprolactinemia. In patients with microadenoma, invasive or non-invasive macroadenoma, and even in patients with visual field defects, dopamine agonists are the first-line treatment. Surgical treatment is indicated in patients who are unresponsive or intolerant to medical treatment or who have persistent neurological signs. Radio therapy should be considered as a supportive treatment for patients in whom surgery fails or medical response is not achieved.en_US
dc.language.isoengen_US
dc.publisherWALTER DE GRUYTER GMBHen_US
dc.identifier.doi10.1515/jpem-2012-0327en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectchildhooden_US
dc.subjectmacroprolactinen_US
dc.subjectprolactinomaen_US
dc.titleClinical and diagnostic characteristics of hyperprolactinemia in childhood and adolescenceen_US
dc.typereviewen_US
dc.relation.journalJOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISMen_US
dc.departmentDBÜen_US
dc.identifier.issue1.Şuben_US
dc.identifier.volume26en_US
dc.identifier.startpage1en_US
dc.identifier.endpage11en_US
dc.contributor.authorID0000-0002-1812-0321en_US
dc.relation.publicationcategoryDiğeren_US
dc.department-temp[Buyukgebiz, Atilla] Bilim Univ, Fac Med, Dept Pediat Endocrinol, Istanbul, Turkey -- [Catli, Gonul -- Abaci, Ayhan -- Bober, Ece] Dokuz Eylul Univ, Fac Med, Dept Pediat Endocrinol, Izmir, Turkeyen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster